Evaluation of cord blood platelet gel for the treatment of skin lesions in children with dystrophic epidermolysis bullosa: pilot study

Objectives: Epidermolysis bullosa (EB) consists of a number of genetically skin diseases characterized by defects in the adhesion of the epidermis to the dermis that cause mechanical fragility of the skin and abnormal wound healing. Wound care is, therefore, of critical importance in the management of EB and current cure are not always satisfactory. In this study, we performed a pilot evaluation of the effectiveness of platelet gel from cord blood (CBPG) as allogeneic product for the treatment of skin lesions in three children with EB. Methods/Study design: Cord blood samples are collected in sterile conditions. These samples were transferred to GMP grade clean room for processing. All CB samples were negative for viral and bacterial infection. Then, bags contain CB were centrifuged and two parts (RBC and PRP) were separated. Gelation was done under sterile condition by adding thrombin within 20-30 minutes. Prepared gel changed twice peer week, time and size of wounds were measured. Results: The clinical outcomes of this small group of patients were shown this trial have high efficiency and effectiveness in compare to the current standard care for these patients. Time of healing and size of wounds decrease significantly. CBPG releases a number of growth factors such as PDGF, TGF-B1 and -B2, IGF, EGF, FGF and EGF which can affect wound healing. Conclusion: In conclusion, this pilot study reveals that CPBG is a promising and safe option for the treatment of EB skin lesions but need for larger studies.